Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

The effects of thymoquinone on pancreatic cancer: Evidence from preclinical studies

  • Monica Butnariu
  • , Cristina Quispe
  • , Jesús Herrera-Bravo
  • , Paweł Helon
  • , Wirginia Kukula-Koch
  • , Víctor López
  • , Francisco Les
  • , Cristian Valdés Vergara
  • , Pedro Alarcón-Zapata
  • , Barbara Alarcón-Zapata
  • , Miquel Martorell
  • , Marius Pentea
  • , Aneta Anca Dragunescu
  • , Ionel Samfira
  • , Zura Yessimsiitova
  • , Sevgi Durna Daştan
  • , Carla Marina Salgado Castillo
  • , Thomas H. Roberts
  • , Javad Sharifi-Rad
  • , Wojciech Koch
  • William C. Cho
  • Banat University of Agricultural Sciences and Veterinary Medicine
  • Universidad Arturo Prat
  • Universidad Santo Tomás, Santiago
  • Universidad de la Frontera
  • Jan Kochanowski University in Kielce
  • Medical University of Lublin
  • San Jorge University
  • University of Zaragoza
  • Universidad Católica del Maule
  • Universidad de Concepción
  • Universidad San Sebastián
  • Al Farabi Kazakh National University
  • Cumhuriyet University
  • Universidad del Azuay
  • University of Sydney
  • Queen Elizabeth Hospital Hong Kong

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

52 Citas (Scopus)

Resumen

Thymoquinone (TQ) is a secondary metabolite found in abundance in very few plant species including Nigella sativa L., Monarda fistulosa L., Thymus vulgaris L. and Satureja montana L. Preclinical pharmacological studies have shown that TQ has many biological activities, such as anti-inflammatory, antioxidant and anticancer. Both in vivo and in vitro experiments have shown that TQ acts as an antitumor agent by altering cell cycle progression, inhibiting cell proliferation, stimulating apoptosis, inhibiting angiogenesis, reducing metastasis and affecting autophagy. In this comprehensive study, the evidence on the pharmacological potential of TQ on pancreatic cancer is reviewed. The positive results of preclinical studies support the view that TQ can be considered as an additional therapeutic agent against pancreatic cancer. The possibilities of success for this compound in human medicine should be further explored through clinical trials.

Idioma originalInglés
Número de artículo113364
PublicaciónBiomedicine and Pharmacotherapy
Volumen153
DOI
EstadoPublicada - sept 2022
Publicado de forma externaSí

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

  1. ODS 3: Salud y bienestar
    ODS 3: Salud y bienestar

Huella

Profundice en los temas de investigación de 'The effects of thymoquinone on pancreatic cancer: Evidence from preclinical studies'. En conjunto forman una huella única.

Citar esto